DUBLIN--(BUSINESS WIRE)--The "Ocular Hypertension Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
This 'Ocular Hypertension - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.
Ocular Hypertension Epidemiology
The epidemiology division's Ocular Hypertension symptoms provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Ocular Hypertension epidemiology segmented as the Prevalent cases of Ocular Hypertension , Gender-specific prevalent case of Ocular Hypertension, Age-specific prevalent cases of Ocular Hypertension and Treated- cases of Ocular Hypertension. The report includes the prevalent scenario of Ocular Hypertension symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Ocular Hypertension (OHT) Epidemiology
The epidemiology segment also provides the Ocular Hypertension (OHT) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent cases of Ocular Hypertension in the 7MM were 20,817,647 in 2020.
Ocular Hypertension Drug Chapters
The drug chapter segment of the Ocular Hypertension report encloses the detailed analysis of Ocular Hypertension marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Ocular Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Prostaglandin analogs (PGAs) are recommended as the first-choice treatment for POAG because of their efficacy, limited systemic side effects, and once-daily dosing. These drugs reduce IOP by stimulating aqueous humor drainage, primarily through the uveoscleral outflow pathway. Latanoprost, bimatoprost, travoprost, and tafluprost, all PGF2a analogues, are currently approved for glaucoma therapy in the US and EU. Beta blockers, combination therapies, carbonic anhydrase inhibitors constitute second line of therapy for treatment of OHT.
Ocular Hypertension Emerging Drugs
NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently being developed by Nicox Ophthalmics in Phase II multicenter, clinical study for the lowering of IOP in patients with OAG or OHT in the US.
Ocular Hypertension Market Outlook
The Ocular Hypertension market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Ocular Hypertension market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Ocular Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Key Findings
This section includes a glimpse of the Ocular Hypertension (OHT) market in 7MM. The market size of OHT in the seven major markets was found to be USD 2,735.0 million in 2020 and market is estimated to increase at a CAGR of 3.82% for the study period (2018-2030).
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Ocular Hypertension Market Overview at a Glance
3.1 Market Share (%) Distribution of Ocular Hypertension in 2018
3.2 Market Share (%) Distribution of Ocular Hypertension in 2030
4 Executive Summary of Ocular Hypertension
5 Disease Background and Overview
5.1 Introduction
5.2 Causes
5.3 Physiology and pathogenesis
5.4 Morphology
5.5 Diagnosis
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of OHT
6.3 Assumption and Rationale
6.4 The United States
6.4.1 Prevalent Cases of Ocular Hypertension in the United States
6.4.2 Gender-specific Prevalence of Ocular Hypertension in the United States
6.4.3 Age-specific Prevalence of Ocular Hypertension in the United States
6.4.4 Treated cases of Ocular Hypertension in the United States
6.5 EU5
6.5.1 Germany
6.5.2 France
6.5.3 Italy
6.5.4 Spain
6.5.5 United Kingdom
6.6 Japan
7 Treatment
7.1 Frequency and follow-up
7.2 Uncertainties regarding best practice for managing ocular hypertension
7.3 Progression to Glaucoma
8 NICE Recommendations and Guidelines
8.1 Case-finding
8.2 Diagnosis
8.3 Standard practice for all assessments
8.4 Reassessment tests
8.5 Treatment
8.6 Stopping treatment for people with OHT or suspected COAG
9 Patient Journey
10 Case Reports
11 Marketed Therapies
11.1 Key Cross- Marketed therapies
11.2 Travoprost ophthalmic solution: Novartis
11.3 Vyzulta (latanoprostene bunod ophthalmic solution): Bausch and Lomb Incorporated
11.4 Zioptan: Merck Sharp and Dohme
11.5 Rhopressa: Aerie Pharmaceuticals
11.6 DURYSTA: Abbvie
11.7 Rocklatan: Aerie Pharmaceutical
11.8 LUMIGAN: Allergan plc
11.9 Betaxon: Alcon Laboratories, Inc.
11.1 COSOPT: Merck Sharp & Dohme Corp.
11.11 Rescula: Ciba Vision
11.12 Alphagan P: Abbvie
11.13 Xelpros: Sun Pharma Advanced Research Company Limited
11.14 Tapcom/ DE-111: Santen Pharmaceutical Co., Ltd.
11.15 Simbrinza: Alcon Research
11.16 GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa Ltd.
11.17 DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research
11.18 Combigan: Allergan
11.19 Azarga: Novartis
11.2 Ganfort: Allergan
11.21 Mikeluna: Otsuka Pharmaceuticals
11.22 AILAMIDE: Senju Pharmaceuticals
11.23 Aibeta: Senju Pharmaceuticals
12 Emerging Therapies
12.1 DE-130A (latanoprost): Santen Pharmaceutical
12.2 NCX 470: Nicox Ophthalmics
12.3 Bamosiran (SYL040012): Sylentis
12.4 Nyxol (Phentolamine Mesylate): Ocuphire Pharma
12.5 POLAT-001: Peregrine Ophthalmic
12.6 Sepetaprost (DE-126/ONO-9054): Santen Inc. /Ono Pharmaceutical
12.7 ENV515 (Travoprost XR): Envisia Therapeutics
12.8 PRO-122: Laboratorios Sophia S.A de C.V.
12.9 DE-117: Santen Inc.
12.10 PDP-716: Sun Pharma
12.11 QLS-101: Qlaris Bio
12.12 ST266: Noveome
13 Ocular Hypertension: 7 Major Market Analysis
13.1 Key Findings
13.2 Market Size of Ocular Hypertension in 7MM
13.3 Market Size of Ocular Hypertension by Therapies by class
13.4 Market Size of Ocular Hypertension for Emerging Therapies by class
13.5 Market Outlook
14 Market Drivers
15 Market Barriers
16 SWOT Analysis
17 Unmet Needs
18 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/875kg1
